eric jonasch, md, explains mk-6482 and the tumor types it will be most effective in
Published 4 years ago • 73 plays • Length 1:42
Download video MP4
Download video MP3
Similar videos
-
1:17
eric jonasch, md, expounds on the use of mk-6482 in both rcc and non-rcc tumors
-
1:52
eric jonasch, md, explains the development process for mk-6482 and hopes for future studies
-
1:38
#kcrs19: eric jonasch, m.d.
-
1:16
dr. jonasch on the safety profile of mk-6482 in von hippel-lindau disease–associated rcc
-
28:46
targeted therapies for the treatment of kidney cancer, eric jonasch, md
-
3:41
a physician faces stage iv #kidneycancer: his advice for you
-
1:01:43
impact of anaemia management on quality of life of ckd patients
-
4:11
musculoskeletal (msk) radiology case #47
-
17:22
mis vs open: the truth in 2017 - john c. france, md
-
27:11
what are the next therapies on the horizon for the treatment of kidney cancer? eric jonasch, md
-
0:30
eric jonasch, md, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy
-
1:11
eric jonasch, md, considers the combination and/or sequencing io and tkis in arcc management
-
1:00
eric jonasch, md, discusses the incidence of von hippel-lindau disease among rcc patients
-
1:04
dr. jonasch on modulating the tumor microenvironment in rcc
-
2:20
brain metastases and kidney cancer: insights from dr. eric jonasch (md anderson cancer center)
-
0:47
eric jonasch, md, on the 4 year checkmate-214 follow up investigating nivolumab ipilimumab
-
26:02
systemic targeted therapy for metastatic renal cell carcinoma in 2012 eric jonasch, m.d
-
1:37
esmo22 highlights: dr. jonasch discusses the cosmic313 trial for kidney cancer
-
0:58
eric jonasch, md, on which non-metastatic renal cell cancer patients should receive adjuvant therapy
-
0:51
eric jonasch, md, on approaches to consider with metastatic non-clear renal cell carcinoma
-
28:11
managing advanced renal cell carcinoma - quinn
-
22:08
frontline treatment for renal cell carcinoma - eric jonasch
Clip.africa.com - Privacy-policy